Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.
Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators. Templeton AJ, et al. Among authors: martin m. Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15. Clin Transl Oncol. 2018. PMID: 29766456
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M. Ethier JL, et al. Among authors: martin m. Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21. Eur J Cancer. 2018. PMID: 29573665
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.
Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Romero A, et al. Among authors: martin m. Clin Transl Oncol. 2014 Apr;16(4):386-94. doi: 10.1007/s12094-013-1088-z. Epub 2013 Aug 2. Clin Transl Oncol. 2014. PMID: 23907291 Clinical Trial.
Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study.
Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing H, Martín M; GEICAM researchers. Castelló A, et al. Among authors: martin m. Br J Cancer. 2014 Sep 23;111(7):1454-62. doi: 10.1038/bjc.2014.434. Epub 2014 Aug 7. Br J Cancer. 2014. PMID: 25101568 Free PMC article.
Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F, Montemuiño S, Martin M, Taboada B, Calvo-Crespo P, Samper-Ots MP, Alcántara P, Corona J, López-Guerra JL, Murcia-Mejía M, López-Mata M, Jové-Teixidó J, Chust M, Díaz-Díaz V, de Ingunza-Barón L, García-Cañibano T, Couselo ML, Del Cerro E, Moradiellos J, Amor S, Varela A, Puertas MM, Thuissard IJ, Sanz-Rosa D, de Dios NR. Couñago F, et al. Among authors: martin m. Clin Transl Oncol. 2019 Jun;21(6):735-744. doi: 10.1007/s12094-018-1976-3. Epub 2018 Nov 14. Clin Transl Oncol. 2019. PMID: 30430394
Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study.
García-Alfonso P, García-González G, Gallego I, Peligros MI, Ortega L, Torres Pérez-Solero G, Sandoval C, Muñoz Martin A, Blanco Codesido M, Calvo Ferrándiz A, Martin M. García-Alfonso P, et al. Among authors: martin m. Clin Transl Oncol. 2021 Jan;23(1):122-129. doi: 10.1007/s12094-020-02402-x. Epub 2020 Jun 9. Clin Transl Oncol. 2021. PMID: 32519179
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
12,545 results
You have reached the last available page of results. Please see the User Guide for more information.